{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:22:27Z","timestamp":1760217747523,"version":"3.41.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Top Institute Pharma"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejphar.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T04:22:28Z","timestamp":1467951748000},"page":"202-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D 2 receptor antagonists in rats"],"prefix":"10.1016","volume":"789","author":[{"given":"Amit","family":"Taneja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dymphy R.H.","family":"Huntjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.M.","family":"De Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes H.","family":"Proost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejphar.2016.07.005_bib1","first-page":"547","article-title":"Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration","volume":"291","author":"Bagli","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"year":"2009","series-title":"NONMEM\u2019s User\u2019s Guides","author":"Beal","key":"10.1016\/j.ejphar.2016.07.005_bib2"},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2007-0017","article-title":"What can we learn from rodents about prolactin in humans?","volume":"29","author":"Ben-Jonathan","year":"2008","journal-title":"Endocr. Rev."},{"year":"2015","series-title":"R:A Language and Environment for Statistical Computing","author":"Core Team","key":"10.1016\/j.ejphar.2016.07.005_bib5"},{"issue":"4","key":"10.1016\/j.ejphar.2016.07.005_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2016.07.005_bib7","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.euroneuro.2007.02.005","article-title":"Risk factors for schizophrenia \u2013 all roads lead to dopamine","volume":"17","author":"Di Forti","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2 Suppl.","key":"10.1016\/j.ejphar.2016.07.005_bib8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2016.07.005_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2008.234","article-title":"An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment","volume":"85","author":"Friberg","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2016.07.005_bib10","unstructured":"Johnson, M., 2012. Translational modelling in schizophrenia \u2013 predicting receptor occupancy (Doctoral Dissertation), University of Groningen, The Netherlands."},{"issue":"3","key":"10.1016\/j.ejphar.2016.07.005_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"7","key":"10.1016\/j.ejphar.2016.07.005_bib13","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s11095-012-0722-8","article-title":"Pharmacokinetic-pharmacodynamic modeling of the D(2) and 5-HT(2A) receptor occupancy of risperidone and paliperidone in rats","volume":"29","author":"Kozielska","year":"2012","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.ejphar.2016.07.005_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN) \u2013 a perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"4","key":"10.1016\/j.ejphar.2016.07.005_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/dmd.108.024125","article-title":"Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid","volume":"37","author":"Liu","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.ejphar.2016.07.005_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2125.2010.03758.x","article-title":"Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin","volume":"70","author":"Ma","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2133\/dmpk.24.16","article-title":"Scaling pharmacodynamics from in vitro and preclinical animal studies to humans","volume":"24","author":"Mager","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.ejphar.2016.07.005_bib20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0022-3565(25)10664-2","article-title":"Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects","volume":"274","author":"Movin-Osswald","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2016.07.005_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejphar.2008.02.005","article-title":"Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics","volume":"584","author":"Olsen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2016.07.005_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1208\/s12248-012-9450-6","article-title":"Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model","volume":"15","author":"Petersson","year":"2013","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.ejphar.2016.07.005_bib23","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.ejphar.2016.07.005_bib24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2016.07.005_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00213-005-0230-1","article-title":"Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data","volume":"184","author":"Rourke","year":"2006","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2016.07.005_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.ejphar.2016.07.005_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","article-title":"Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors","volume":"16","author":"Seeman","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.ejphar.2016.07.005_bib28","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s11095-009-9907-1","article-title":"A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs","volume":"26","author":"Stevens","year":"2009","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejphar.2016.07.005_bib29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.111.040782","article-title":"Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration","volume":"39","author":"Stevens","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"13\u201314","key":"10.1016\/j.ejphar.2016.07.005_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jchromb.2010.02.024","article-title":"Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples","volume":"878","author":"Stevens","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2016.07.005_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10928-012-9262-4","article-title":"Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans","volume":"39","author":"Stevens","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejphar.2016.07.005_bib32","unstructured":"Taneja, A., Vermeulen, A., Huntjens, D.R.H., Danhof, M., De Lange, E.C.M., Proost, J.H., 2016. Evaluation of different potencies of risperidone and paliperidone and exploration of appropriate parameterization of drug effects for risperidone, paliperidone and remoxipride. Data in brief (in press)."},{"issue":"11","key":"10.1016\/j.ejphar.2016.07.005_bib33","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s11095-007-9336-y","article-title":"Allometric scaling of pharmacodynamic responses: application to 5-HT1A receptor mediated responses from rat to man","volume":"24","author":"Zuideveld","year":"2007","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:18:14Z","timestamp":1748996294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916304356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":33,"alternative-id":["S0014299916304356"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.005","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}